Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders"

Research output: Contribution to journalArticle

271 Scopus citations

Abstract

UDCA exerts its beneficial effect in liver diseases through a diverse, probably, complementary array of mechanisms. The clinical use and efficacy of UDCA in PBC have been evident. UDCA may also have a place in the management of PSC, ICP, cystic fibrosis, PFIC and GVHD involving the liver, although, more studies are needed to further determine its therapeutic potential in these diseases and in other hepatobiliary disorders such as liver allograft rejection, drug and TPN-induced cholestasis, NASH, and alcoholic liver disease.

Original languageEnglish (US)
Pages (from-to)134-146
Number of pages13
JournalJournal of Hepatology
Volume35
Issue number1
DOIs
Publication statusPublished - 2001
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Ursodeoxycholic acid "mechanisms of action and clinical use in hepatobiliary disorders". / Lazaridis, Konstantinos N.; Gores, Gregory J.; Lindor, Keith.

In: Journal of Hepatology, Vol. 35, No. 1, 2001, p. 134-146.

Research output: Contribution to journalArticle